3 news items
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI
1 Jun 24
."
No new safety signals were identified as of the data cut-off date
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
8 May 24
Initiated the Phase 2 SENTRY-2 trial (XPORT-MF-044; NCT05980806), evaluating the efficacy and safety of selinexor monotherapy at 60 mg QW or 40 mg QW
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
KPTI
24 Apr 24
).SELECT IMPORTANT SAFETY INFORMATION
- Prev
- 1
- Next